samedan logo
 
 
spacer
home > pmps > autumn 2008 > integrating isolation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Integrating Isolation

Remaining competitive in pharmaceutical development and production can be a challenge as it becomes more complex to get products through clinical trials and then to eventually produce them. In order to remain competitive, pharmaceutical companies need to develop products faster and more cost-effectively. At the same, time, they need to protect workers from increasingly hazardous drugs in both the clinical trials phase and during the manufacturing process.

In order to meet these trends costeffectively, many pharmaceutical companies will need to increase automation and flexibility within their facilities, while separating the production environment from operators. Combining these initiatives within a single technology platform is making it economically feasible to meet these challenges and still compete effectively.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Felix Nink studied Mechanical Engineering at Koblenz University. He has worked for Robert Bosch GmbH Packaging Technology since 2000, beginning his career as a Mechanical Designer in the capsule filling and checkweighing department. He gained experience as Application Engineer and Project Leader of several turnkey encapsulation projects for the pharmaceutical industry. Since 2004, Felix has been a Product Manager, with responsibility for capsule filling and checkweighing machines worldwide.
spacer
Felix Nink
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement